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Purpose or Objective: Transanal Endoscopic Microsurgery 
(TEM) and Radiotherapy in Early Rectal Cancer (TREC) [1][2] 
is a randomised phase II feasibility study to compare radical 
TEM surgery versus short course pre-operative radiotherapy 
(25Gy in 5 fractions over 5 days) with delayed local excision 
for treatment of early rectal cancer. 
The QA programme for TREC is co-ordinated by the UK 
Radiotherapy Trials Quality Assurance (RTTQA) group [3][4]. 
We describe the development of a standardised analysis 
pipeline and the results of this analysis. 
 
Material and Methods: To ensure consistency and therefore 
comparability between radiotherapy centres involved in 
TREC, a detailed radiotherapy protocol was developed. To 
assess the quality of the plans, 3 (PTVmin, PTVmax, 
ICRUmax) quantities were measured and recorded. Further 
investigation was carried out if the relevant objective was 
not met. 
TEMS patients in TREC were treated across 18 UK centres. 
Radiotherapy plan data was submitted for each of the 87 TEM 
patients in DICOM format and processed with the 
Computational Environment for Radiotherapy Research 
(CERR) software [5]. This enabled i) outlining of target and 
organ-at-risk structures, ii) dose distribution and dose volume 
histograms to be assessed (independently) and iii) data 
format standardisation and automated analysis.  
 
Results: 
 
 
Table 1 shows the ROI objectives outlined in the TREC 
protocol. Figure 1 shows the distribution of PTV coverage for 
the 87 TEM patients analysed. All plans achieved D2%<110% 
(Figure 1, marker A) and 95% of plans achieved D5%<105% (B). 
Cases of poor coverage (C) were investigated and in 4 cases it 
was found that the outlined PTV extended beyond the patient 
surface. In these cases PTV was retracted to within the 
patient surface and coverage was recalculated. 
 
Conclusion: Deviation from the clinical trial protocol has the 
potential to confound the study question and quality 
assurance is therefore essential when comparing different 
treatments. A high level of conformance was found across the 
18 treating centres, with 95% of plans achieving both the 
minimum and maximum PTV objectives. Our analysis of the 
radiotherapy plans demonstrates good understanding and 
adherence to the TREC protocol. 
STAR-TREC is an upcoming trial that will amend and extend 
the TREC pilot. RTTQA findings from TREC will be used to 
strengthen and improve the STAR-TREC protocol, for 
example, use of standardised structure names and use of 
plan-optimisation PTVs to assess target coverage. 
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Purpose or Objective: End-to-end tests are used to measure 
the overall accuracy of the radiation therapy chain, excluding 
patient specific factors. An end-to-end test is a prerequisite 
to the overall success of any IGRT program. In this work the 
performance of a cost-effective and fast end-to-end test to 
assess the geometrical accuracy of the radiotherapy workflow 
is described.  
 
Material and Methods: The in-house developed phantom for 
end-to-end testing is depicted in figure 1a. It consists of two 
Perspex slabs in which a piece of Gafchromic EBT3 film of 
4x4cm2 can be placed in. Two notches tighten the film and 
determine the center and the orientation of the 
phantom/film respectively. The phantom can be positioned 
in such a way to have the film in the coronal and sagittal 
orientation. The total weight of the phantom is about 1kg. A 
high resolution computed tomography (CT) scan is made of 
the phantom and a treatment plan (figure 1b) including 
collimator, gantry and table rotations is computed on this CT. 
The treatment plan is sent to the linear accelerator. 
Simulating an actual patient treatment, the phantom is set 
up on the treatment table using the lasers. Then, cone beam 
CT guidance is used to adjust the phantom’s position with 
respect to the planning CT. After applying the suggested 
table shift the plan is irradiated. The films are analyzed using 
an in-house written Excel macro. The shift required to align 
the film with the calculated dose plane represents the 
targeting error. The use of the described phantom for end-to-
end testing was compared against two commercial available 
phantoms. 
 
 
 
Results: The phantom is light, easy to handle and to set up. 
Moreover, it is cheap compared to available commercial 
systems. The phantom allows to assess the overall 
geometrical accuracy of the treatment chain with sub mm 
